PDCD1 and non-small cell lung carcinoma: In a multicentre, randomized phase 2 study (PEMBRO‐RT) of 92 patients with advanced NSCLC, better outcomes were observed when SBRT (3 times 8 Gy) was administered 7 days before the anti‐PD1 agent pembrolizumab compared to the nonirradiated group (Theelen et al., 2019).